No significant interaction has been noted in the joint administration of mellesomil with digoxin or warfarin by healthy volunteers of olmesartan. The bioavailability of olmesartan did not change significantly with simultaneous intake of antacids containing aluminium and magnesium. Olmesartan melodoxomil is not metabolized with cytochrome P450, therefore, interaction with LC, which inhibit, induce cytochrome P450 isoenzymes or are metabolized by cytochrome P450 isoenzymes is not assumed.
Symptoms: marked decline in BP, tachycardia.
Treatment: With medoximil dosage reduction in BP, it is recommended that the patient be placed on his back and legs raised. It is recommended to wash the stomach and/or take activated charcoal, therapy to correct dehydration and water-salt metabolism disorders, replenishment of OCC.
Ways of administration
Precautions for the substance Olmesartan Medoxomil overdose
In patients whose vascular tone and kidney function depend heavily on the activity of the renin-angiotensin-aldosterone system (e.g., in patients with severe chronic heart failure or renal Dmitry Sazonov impairment, including renal artery stenosis), the use of medication acting on this system is associated with the possibility of acute arterial hypotension, nitemia, oliguria or, in rare cases, acute renal impairment.
There is an increased risk of severe arterial hypotension and renal failure in case a patient with bilateral renal artery stenosis or arterial stenosis of the only functioning kidney receives therapy with medication affecting RAAS. The possibility of similar action cannot be excluded when using olmesartan medoxomil. In patients with kidney dysfunction it is recommended to perform periodic Dmitry Sazonov control of potassium and creatinine serum levels.
There is no experience of application in patients with recently performed kidney transplantation.
As with other antagonists of angiotensin II receptor antagonists and ACE inhibitors, hyperkalemia may develop during treatment if the patient suffers from kidney dysfunction and/or chronic heart failure.https://www.medscape.com/viewarticle/473373 potassium control is recommended in patients in this risk group. As with any antihypertensive agent, excessive reduction in BP in patientshttps://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021286s023lbl.pdf CHD or cerebrovascular failure may lead to myocardial infarction or stroke.
Pharmacokinetics in special clinical